Prosecution Insights
Prosecution Insights
8 pending office actions • 7 clients • 7 examiners • 7 art units • 0 of 8 (0%) have an AI response strategy ready • 10 patents granted in the last 365 days
Based on the USPTO statutory response window for each pending office action. 8 of the docket's apps have a known mailing date; the rest are excluded from the tile counts.
Every pending office action with a known statutory deadline, placed on a days-until-due axis. Dots left of Today are overdue; the further right, the more runway. Cases that share a deadline window stack vertically. 8 of the docket's apps have a known mailing date.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| §103 only | 1 (12%) |
| §112 only | 3 (38%) |
| Double-patenting only | 1 (12%) |
| No statute on record | 3 (38%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| MOSELEY II, NELSON B | 2 | 68.1% | +41.7% |
| BERRY, LAYLA D | 1 | 65.9% | +8.6% |
| PAGANO, ALEXANDER R | 1 | 78.8% | +11.5% |
| MONTANARI, DAVID A | 1 | 65.1% | +49.6% |
| HUYNH, PHUONG N | 1 | 65.7% | +53.3% |
| BUNNER, BRIDGET E | 1 | 64.4% | +19.7% |
| HABTE, KAHSAY | 1 | 84.9% | +7.3% |
Cases in front of an examiner with an allow rate of 80%+ where the difficulty is Easy or Medium. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 17367726 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | HABTE, KAHSAY | 19d overdue |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 6 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18421494 | IRON COMPLEX COMPOUNDS FOR THERAPUTIC USE | PAGANO, ALEXANDER R | 59d overdue |
| 18490804 | MULTISPECIFIC NKp46 BINDING PROTEINS | HUYNH, PHUONG N | 44d overdue |
| 18507469 | METHODS FOR TREATING CANCER USING T CELLS WHICH EXPRESS A CHIMERIC NK RECEPTOR | MONTANARI, DAVID A | 7d |
| 18125762 | REDUCING FRATRICIDE OF IMMUNE CELLS EXPRESSING NKG2D-BASED RECEPTORS | MOSELEY II, NELSON B | 28d |
| 18178783 | COMPOUND TARGETING IL-23A AND TNF-ALPHA AND USES THEREOF | BUNNER, BRIDGET E | 28d |
| 17739400 | COLON AND PANCREAS CANCER SPECIFIC ANTIGENS AND ANTIBODIES | MOSELEY II, NELSON B | 63d |
| Client (Assignee) | Pending OAs |
|---|---|
| Pharmacosmos Holding A/S | 2 |
| Dartmouth College | 1 |
| INNATE PHARMA | 1 |
| Celyad | 1 |
| MACROGENICS, INC. | 1 |
| Precision Biologics, Inc. | 1 |
| BEIJING TIDE PHARMACEUTICAL CO., LTD. | 1 |
| Art Unit | Apps |
|---|---|
| 1642 | 2 |
| 1623 | 1 |
| 1692 | 1 |
| 1632 | 1 |
| 1641 | 1 |
| 1647 | 1 |
| 1624 | 1 |
| App # | Title | Client | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|---|
| 18294572 | IRON COMPLEX COMPOUNDS FOR SUBCUTANEOUS USE IN THERAPY OF IRON DEFICIENCY IN COMPANION ANIMALS | Pharmacosmos Holding A/S | BERRY, LAYLA D | 1623 | DP | Non-Final OA | 83d | Pending | Feb 02, 2024 |
| 18421494 | IRON COMPLEX COMPOUNDS FOR THERAPUTIC USE | Pharmacosmos Holding A/S | PAGANO, ALEXANDER R | 1692 | Other | Final Rejection | 59d overdue | Pending | Jan 24, 2024 |
| 18507469 | METHODS FOR TREATING CANCER USING T CELLS WHICH EXPRESS A CHIMERIC NK RECEPTOR | The Trustees of Dartmouth College | MONTANARI, DAVID A | 1632 | §112 | Non-Final OA | 7d | Pending | Nov 13, 2023 |
| 18490804 | MULTISPECIFIC NKp46 BINDING PROTEINS | Innate Pharma | HUYNH, PHUONG N | 1641 | §112 | Non-Final OA | 44d overdue | Pending | Oct 20, 2023 |
| 18125762 | REDUCING FRATRICIDE OF IMMUNE CELLS EXPRESSING NKG2D-BASED RECEPTORS | Celyad S.A. | MOSELEY II, NELSON B | 1642 | Other | Non-Final OA | 28d | Pending | Mar 24, 2023 |
| 18178783 | COMPOUND TARGETING IL-23A AND TNF-ALPHA AND USES THEREOF | Macrogenics, Inc. | BUNNER, BRIDGET E | 1647 | Other | Non-Final OA | 28d | Pending | Mar 06, 2023 |
| 17739400 | COLON AND PANCREAS CANCER SPECIFIC ANTIGENS AND ANTIBODIES | Precision Biologics, Inc. | MOSELEY II, NELSON B | 1642 | §112 | Final Rejection | 63d | Pending | May 09, 2022 |
| 17367726 | RHO-ASSOCIATED PROTEIN KINASE INHIBITOR, PHARMACEUTICAL COMPOSITION COMPRISING SAME, AND PREPARATION METHOD AND USE THEREOF | BEIJING TIDE PHARMACEUTICAL CO., LTD. | HABTE, KAHSAY | 1624 | §103 | Non-Final OA | 19d overdue | Pending | Jul 06, 2021 |
IP Author helps law firms respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free Trial